Chromogenic Factor VIII

B-domain deleted extended half-life factor VIII concentrates have come to be the chosen hemophilia A therapies, along with emicizumab [HemLibra®], approved in 2017. Coagulation laboratories can no longer rely upon the time-honored one-stage clot-based factor assay to accurately report BDD EHL therapeutic factor VIII activity, nor can these tests be used to monitor patient factor […]

Comments (0)

Bleeding Disorders

Feb 10 2021

george

Hemophilia A Management

Here is a link to New Frontiers in Hemophilia A Management [click], which appears in the December 2020 Clinical Laboratory News, an AACC Publication. The article features the rapid increase of emicizumab [HemLibra®] therapy and the need for bovine substrate chromogenic factor VIII assays to replace the unreliable clot-based assays. The article is a good […]

Bleeding Disorders

Emicizumab’s Effect on the PTT

Here is an informative December 2020 CAP Today article, “Digging Into Drug’s Effect on aPTT-based Assays” [click] by staff writer Amy Carpenter Aquino. The article documents a CAP20 hemophilia therapy session, “aPTT assays in patients on emicizumab are not going to be accurate. And the effect of the drug on our aPTT-based assays can last […]

Bleeding Disorders

New 2021 VWD Dx and Rx Guides

Today, 1-12-21, the World Federation of Hemophilia elearning service [click] published their an update series of von Willebrand disease diagnosis and management guidelines in Blood Advances 2021; 5; DOI 10.1182/bloodadvances.2020003264. Thanks to Elaine Benoit, Precision BioLogic Inc., for the heads-up. These essential documents are free of charge.

Bleeding Disorders

Cord Blood PTT

From Ann Helen: Can you trust results of PTT and factor VIII in umbilical cord blood? It seems as if it is usual to draw umbilical cord blood from newborns when the mother is a known carrier of Hemophilia A. Can you trust a high APTT and a low factor VIII in such a sample? […]

Bleeding Disorders

Webinar: Von Willebrand Factor: Friend or Foe

Click here to register for our webinar, von Willebrand Factor, Friend or Foe. Von Willebrand Factor (VWF) is crucial to platelet adhesion and proper, effective coagulation. It also appears to be associated with inflammation and sepsis. Join us for a thought-provoking webinar entitled Von Willebrand Factor: Friend or Foe? as we explore the many faces […]

Bleeding Disorders

December 2020 QQ: Emicixumab Responses

Here are the responses to our December, 2020 Quick Question: “What therapeutic does your center use for hemophilia A patients with inhibitors who bleed during emicizumab therapy?” There were only 6 voters Activated prothrombin complex concentrate [APCC]: 0 Recombinant activated factor VII [rFVIIa]: 4 Low-dose factor VIII: 1 High-dose factor VIII: 0 None, we see […]

Bleeding Disorders

CLS Journal Hemostasis Articles

A recent 2020 Clinical Laboratory Science Journal, publication of the American Society for Clinical Laboratory Science, offers the following hemostasis-related articles, purchasable for $5 each: Nardi MA. Emicizumab and the clinical laboratory. DOI: https://doi.org/10.29074/ascls.119.002204 Ketelson B. Molecular action of ADAMTS13 and transfusion therapies of thrombotic thrombocytopenia pupura. DOI: https://doi.org/10.29074/ascls.120.002287 Ketelson B. An overview of the […]

Bleeding Disorders

December 2020 Quick Question: Emicizumab

Our December, 2020 Quick Question addresses the uncommon incidence of breakthrough bleeds in hemophilia A patient who are being treated with emicizumab [HEMLIBRA], the immunotherapeutic that bypasses factor VIII. Treatment may become an issue in severe hemophilia in which patients develop inhibitors. See our November 29 post, Emicizumab Laboratory Assay Review [click] for some hints […]

Bleeding Disorders

November 2020 QQ: VWF Activity Assay Responses

Our November, 2020 Quick Question attracted 37 participants. Here is the stem: “Which VWF activity assay is preferred at your facility [check 10-31-20 post]?” The selections were… VWF:RCo: 58% [21] VWF:GP1bR: 3% [1] VWF:GP1gM: 14% [5] VWF:Ab: 3% [1] VWF:CBA: 22% [8]* The time-honored Ristocetin cofactor assay remains the most prevalent of VWF activity assays. […]

Comments (0)

Bleeding Disorders

Bleeding Disorders

Chromogenic Factor VIII

Hemophilia A Management

Emicizumab’s Effect on the PTT

New 2021 VWD Dx and Rx Guides

Cord Blood PTT

Webinar: Von Willebrand Factor: Friend or Foe

December 2020 QQ: Emicixumab Responses

CLS Journal Hemostasis Articles

December 2020 Quick Question: Emicizumab

November 2020 QQ: VWF Activity Assay Responses

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question